PTGX
Protagonist Therapeutics Inc

3,365
Mkt Cap
$5.6B
Volume
1.47M
52W High
$93.25
52W Low
$33.70
PE Ratio
141.54
PTGX Fundamentals
Price
$89.65
Prev Close
$87.33
Open
$87.96
50D MA
$78.31
Beta
0.53
Avg. Volume
907,574.47
EPS (Annual)
$4.23
P/B
8.67
Rev/Employee
$3.45M
Loading...
Loading...
News
all
press releases
Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera
(RTTNews) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV). The data...
Nasdaq News: Markets·5h ago
News Placeholder
More News
News Placeholder
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Protagonist Therapeutics, Inc. (Protagonist) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients...
Business Wire·7h ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by American Century Companies Inc.
American Century Companies Inc. boosted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 18.7% during the second quarter, according to the company in its most...
MarketBeat·7d ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Creative Planning
Creative Planning grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 74.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·9d ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 864.8% in the second quarter, according to the...
MarketBeat·10d ago
News Placeholder
Protagonist Therapeutics Reaches Analyst Target Price
In recent trading, shares of Protagonist Therapeutics Inc (Symbol: PTGX) have crossed above the average analyst 12-month target price of $89.77, changing hands for $89.86/share. When a stock reaches...
Nasdaq News: Markets·10d ago
News Placeholder
Intech Investment Management LLC Acquires 2,971 Shares of Protagonist Therapeutics, Inc. $PTGX
Intech Investment Management LLC lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 9.6% in the second quarter, according to the company in its most recent filing...
MarketBeat·13d ago
News Placeholder
Envestnet Asset Management Inc. Grows Position in Protagonist Therapeutics, Inc. $PTGX
Envestnet Asset Management Inc. raised its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 43.2% in the second quarter, according to the company in its most recent disclosure...
MarketBeat·16d ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Aviva PLC
Aviva PLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 28.5% during the 2nd quarter, according to its most recent disclosure with the Securities...
MarketBeat·22d ago
News Placeholder
135,050 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Nan Fung Trinity HK Ltd.
Nan Fung Trinity HK Ltd. purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The...
MarketBeat·23d ago

Latest PTGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.